JP2024515169A5 - - Google Patents
Info
- Publication number
- JP2024515169A5 JP2024515169A5 JP2023562501A JP2023562501A JP2024515169A5 JP 2024515169 A5 JP2024515169 A5 JP 2024515169A5 JP 2023562501 A JP2023562501 A JP 2023562501A JP 2023562501 A JP2023562501 A JP 2023562501A JP 2024515169 A5 JP2024515169 A5 JP 2024515169A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- natural killer
- population
- combination
- killer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172401P | 2021-04-08 | 2021-04-08 | |
| US63/172,401 | 2021-04-08 | ||
| US202163290349P | 2021-12-16 | 2021-12-16 | |
| US63/290,349 | 2021-12-16 | ||
| PCT/US2022/023660 WO2022216815A1 (en) | 2021-04-08 | 2022-04-06 | Treatment of cancer with nk cells and a cd20 targeted antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515169A JP2024515169A (ja) | 2024-04-05 |
| JP2024515169A5 true JP2024515169A5 (enExample) | 2025-04-14 |
Family
ID=83546502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562501A Withdrawn JP2024515169A (ja) | 2021-04-08 | 2022-04-06 | Ｎｋ細胞およびｃｄ２０標的抗体を用いた癌治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240180962A1 (enExample) |
| EP (1) | EP4319769A4 (enExample) |
| JP (1) | JP2024515169A (enExample) |
| KR (1) | KR20240024046A (enExample) |
| AU (1) | AU2022254978A1 (enExample) |
| WO (1) | WO2022216815A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| EP3633029A4 (en) | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| KR102774451B1 (ko) | 2017-11-14 | 2025-02-28 | 앱클론(주) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| AU2019381526B2 (en) | 2018-11-14 | 2023-02-23 | Green Cross Lab Cell Corporation | Method for culturing cord blood-derived natural killer cells using transformed T-cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6961490B2 (ja) * | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| EP4101447A1 (en) * | 2016-06-30 | 2022-12-14 | Nant Holdings IP, LLC | Nant cancer vaccine |
| WO2018027135A1 (en) * | 2016-08-04 | 2018-02-08 | Unum Therapeutics Inc. | Treatment of lymphoma using antibody-coupled t cell receptor |
| EP3567049A4 (en) * | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| JP7383620B2 (ja) * | 2018-01-31 | 2023-11-20 | セルジーン コーポレイション | 養子細胞療法およびチェックポイント阻害剤を使用する併用療法 |
| AU2019271146A1 (en) * | 2018-05-14 | 2020-12-10 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
| US20240000840A1 (en) * | 2020-12-17 | 2024-01-04 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a cd20 targeted antibody |
-
2022
- 2022-04-06 KR KR1020237038551A patent/KR20240024046A/ko not_active Withdrawn
- 2022-04-06 WO PCT/US2022/023660 patent/WO2022216815A1/en not_active Ceased
- 2022-04-06 AU AU2022254978A patent/AU2022254978A1/en not_active Abandoned
- 2022-04-06 EP EP22785367.8A patent/EP4319769A4/en active Pending
- 2022-04-06 US US18/285,637 patent/US20240180962A1/en active Pending
- 2022-04-06 JP JP2023562501A patent/JP2024515169A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024515169A5 (enExample) | ||
| JP2024513958A5 (enExample) | ||
| JP2024513522A5 (enExample) | ||
| US6544787B1 (en) | Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation | |
| ES2224122T3 (es) | Inmunoterapia de cancer con linfocitos alogenicos. | |
| CN102271702B (zh) | 抗第三方中枢记忆性t细胞、产生其的方法及其在移植和疾病治疗中的用途 | |
| Mehta et al. | Graft-versus-myeloma | |
| Maeda et al. | Critical role of host γδ T cells in experimental acute graft-versus-host disease | |
| CN103282047B (zh) | 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途 | |
| JP2024513514A5 (enExample) | ||
| JP2024527559A5 (enExample) | ||
| Nanjappa et al. | Intrinsic MyD88-Akt1-mTOR signaling coordinates disparate Tc17 and Tc1 responses during vaccine immunity against fungal pneumonia | |
| CN115137752A (zh) | 用于干细胞移植的方法 | |
| Buckley | B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review | |
| JP2024516619A5 (enExample) | ||
| JP2022023136A5 (enExample) | ||
| Li et al. | Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells | |
| Su et al. | Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells | |
| JP2002534083A (ja) | 骨髄機能廃絶性ではない寛容原性の処置 | |
| JP3541950B2 (ja) | 癌およびウイルス性疾患を治療するための改変化ｔａｌｌ−１０４細胞の使用 | |
| Saavedra | Immunomodulatory Impact Of Memory T Lymphocytes In Periodontitis | |
| de Paula | Immunomodulatory Impact of Memory T Lymphocytes in Periodontitis | |
| Marinkovic et al. | Selective inflammation of the tumor microenvironment and invigorated T cell-mediated tumor control upon induced systemic inactivation of TREX1 | |
| Herberman | Therapy of cancer with interleukin-2-activated natural killer cells | |
| Humphrey | 1. Role of Natural Killer (NK) Cells in Resistance |